

AMENDMENTS TO THE CLAIMS

Claims 1-25 (canceled).

Claim 26 (currently amended) A method of producing activated T cells directed towards stratum corneum chymotryptic enzyme (SCCE) in an individual with ovarian cancer, prostate cancer or breast cancer, comprising the steps of:

exposing dendritic cells to a human SCCE peptide selected from the group consisting of SEQ ID NOs: 31, 32, 33, 34, 35, 36, 80, 86, 99 or the human SCCE protein encoded by the DNA of SEQ ID NO: 30, thereby producing activated dendritic cells; and

exposing said activated dendritic cells to T cells, wherein said activated dendritic cells would present said SCCE peptide to said T cells, thereby producing activated T cells directed toward said SCCE in the individual with ovarian cancer, prostate cancer or breast cancer.

Claims 27-29 (canceled).

Claim 30 (currently amended) The method of claim 26, wherein said dendritic cells are isolated from [[an]] the individual prior to said exposure to said

SCCE polypeptide, wherein said activated dendritic cells are reintroduced into said individual subsequent to said exposure.

Claim 31-39 (canceled).